The landscape of psoriasis provision in the UK. (1st December 2020)

• Record Type: Journal Article
• Authors: Smith, S. P.; Mohd Mustapa, M. F.; Berker, D.
• Is Part Of: Clinical and experimental dermatology. Volume 45:Number 8(2020)
• Page Start: 1040
• Page End: 1043
• Publication Date: 2020-12-01
• Subjects: Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/ced.14286
• Languages: English
• ISSNs: 0307-6938

Abstract

Summary: Psoriasis remains one of the commonest conditions seen in dermatological practice, and its treatment is one of the greatest cost burdens for the UK National Health Service. Treatment of psoriasis is complex, with numerous overlapping lines and therapies used in combination. This complexity reflects the underlying pathophysiology of the disease as well as the heterogeneous population that it affects. National Institute for Health and Care Excellence (NICE) guidance for the treatment of psoriasis has been available since 2013, and has been the subject of three national audits conducted by the British Association of Dermatologists. This report synthesizes the results of the most recent of those exercises and places it in the context of the NICE guidance and previous audits. It clearly shows the significant burden of disease, issues with provision of services and long waiting times and the marked shift in therapies towards targeted biologic therapies.